Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Recombinant Von Willebrand Factor Administration: Dosing Considerations and Rapid Stabilization of Endogenous Plasma FVIII Levels in Patients with Severe Von Willebrand Disease

Joan Cox Gill, MD, Pier Mannuccio Mannucci, Margaret V. Ragni, MD MPH, Giancarlo Castaman, Flora Peyvandi, Bettina Ploder, Aaron Novack, Peter Chen, Arthur Sytkowski, Bruce Ewenstein

Blood (2017) 130 (Supplement 1): 3682.

https://doi.org/10.1182/blood.V130.Suppl_1.3682.3682

Published: 2017

Journal Articles

Estimating the Cost Savings and Cost Effectiveness of Low Dose Immune Tolerance Induction (ITI) Therapy with Bypassing Agent Prophylaxis Compared to High Dose ITI and Low Dose ITI

Gili Kenet, MD, Abiola Oladapo, PhD BPharm, Josh Epstein, PhD, Thompson Christin, PhD, Aaron Novack, Diane J. Nugent, MD

Blood (2017) 130 (Supplement 1): 4632.

https://doi.org/10.1182/blood.V130.Suppl_1.4632.4632

Published: 2017

Journal Articles

Four Decade Cumulative Review of Thrombo-Embolic Events Reported with the Use of Activated Prothrombin Complex Concentrate in Congenital Haemophilia

Roberto Crea, DVM, MSc, Aaron Novack, Armin J Reininger, Justine Kennedy, Sandra Raff, Alessandro Gringeri, MD MSc, Naghmana Bajwa

Blood (2016) 128 (22): 5031.

https://doi.org/10.1182/blood.V128.22.5031.5031

Published: 2016

Journal Articles

The Effect of Inhibitory Antibodies on Acute Treatment of Bleeding Episodes with OΒΙ-1, an Antihemophilic Factor VIII (recombinant), Porcine Sequence, in Patients with Acquired Hemophilia Α

Heinrich D. Farin, MD, Aaron Novack, PhD, Min Mo, PhD, Christelle Bourgeois, PhD, Frank M Horling, PhD, Bruce M. Ewenstein, MD PhD

Blood (2014) 124 (21): 2831.

https://doi.org/10.1182/blood.V124.21.2831.2831

Published: 2014

Journal Articles

The Benefit of FVIII Measurement: Tailored Treatment with Obi-1, a Recombinant Porcine Sequence Factor VIII, in Subjects with Acquired Hemophilia a

Abiola Oladapo, PhD, Joshua Epstein, PhD, Aaron Novack, PhD, Heinrich D. Farin, MD

Blood (2014) 124 (21): 3509.

https://doi.org/10.1182/blood.V124.21.3509.3509

Published: 2014

Journal Articles

Treatment Of Serious Bleeds With a B-Domain Deleted Recombinant Porcine Sequence Factor VIII (OBI-1) In Patients With Acquired Hemophilia A: A Prospective Clinical Trial

Rebecca Kruse-Jarres, MD, MPH, Jean St. Louis, MD, Anne Greist, MD, Amy D. Shapiro, MD, Hedy Smith, MD PhD, Pratima Chowdary, MBBS, FRCP, FRCPath, Anja B Drebes, MRCP, FRCPath, Edward D. Gomperts, MD, Miranda Chapman, Min Mo, Aaron Novack, PhD, Heinrich D. Farin, MD

Blood (2013) 122 (21): 206.

https://doi.org/10.1182/blood.V122.21.206.206

Published: 2013

NARROW

Recombinant Von Willebrand Factor Administration: Dosing Considerations and Rapid Stabilization of Endogenous Plasma FVIII Levels in Patients with Severe Von Willebrand Disease

Estimating the Cost Savings and Cost Effectiveness of Low Dose Immune Tolerance Induction (ITI) Therapy with Bypassing Agent Prophylaxis Compared to High Dose ITI and Low Dose ITI

Four Decade Cumulative Review of Thrombo-Embolic Events Reported with the Use of Activated Prothrombin Complex Concentrate in Congenital Haemophilia

The Effect of Inhibitory Antibodies on Acute Treatment of Bleeding Episodes with OΒΙ-1, an Antihemophilic Factor VIII (recombinant), Porcine Sequence, in Patients with Acquired Hemophilia Α

The Benefit of FVIII Measurement: Tailored Treatment with Obi-1, a Recombinant Porcine Sequence Factor VIII, in Subjects with Acquired Hemophilia a

Treatment Of Serious Bleeds With a B-Domain Deleted Recombinant Porcine Sequence Factor VIII (OBI-1) In Patients With Acquired Hemophilia A: A Prospective Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

Recombinant Von Willebrand Factor Administration: Dosing Considerations and Rapid Stabilization of Endogenous Plasma FVIII Levels in Patients with Severe Von Willebrand Disease

Estimating the Cost Savings and Cost Effectiveness of Low Dose Immune Tolerance Induction (ITI) Therapy with Bypassing Agent Prophylaxis Compared to High Dose ITI and Low Dose ITI

Four Decade Cumulative Review of Thrombo-Embolic Events Reported with the Use of Activated Prothrombin Complex Concentrate in Congenital Haemophilia

The Effect of Inhibitory Antibodies on Acute Treatment of Bleeding Episodes with OΒΙ-1, an Antihemophilic Factor VIII (recombinant), Porcine Sequence, in Patients with Acquired Hemophilia Α

The Benefit of FVIII Measurement: Tailored Treatment with Obi-1, a Recombinant Porcine Sequence Factor VIII, in Subjects with Acquired Hemophilia a

Treatment Of Serious Bleeds With a B-Domain Deleted Recombinant Porcine Sequence Factor VIII (OBI-1) In Patients With Acquired Hemophilia A: A Prospective Clinical Trial

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only